A “Dream” approach to detecting cancer with tumor-derived extracellular vesicles

Researchers at Qingdao University have developed an innovative method for detecting cancer using tiny biological messengers called extracellular vesicles (EVs). These vesicles are released by cells, including tumor cells, and carry important molecular signals that can reveal what is happening inside the body. Because they circulate in blood, they offer a promising route for noninvasive cancer diagnosis.

The challenge, however, is that tumor-derived EVs (tEVs) are incredibly diverse and can be hard to distinguish from normal EVs in the blood. To tackle this problem, the researchers created a new detection method called DREAM, short for Dual Recognition-Enabled Amplification. This technique uses two aptamers, short pieces of DNA or RNA that bind specific targets, to recognize two different proteins on the surface of cancer-derived EVs. When both aptamers bind their targets, it triggers a DNA-based signal amplification process that makes the vesicles easier to detect using fluorescence.

The researchers tested DREAM using EVs from pancreatic cancer cells and showed it could accurately detect these cancer signals in blood samples. Even more impressively, the method distinguished pancreatic cancer patients from both healthy individuals and people with other types of cancer. Because the system can be easily customized for different types of tumors, it holds strong potential for broad cancer screening applications.

By combining precision recognition and signal amplification, the DREAM strategy offers a new way to harness the diagnostic potential of extracellular vesicles, and makes progress toward truly noninvasive early cancer detection.